Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap. (Q53647222)

16 May 2018

title

Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap. (English)

1 reference

16 May 2018

1 reference

2

1 reference

16 May 2018

Hiromitsu Nakauchi

4

object named as

Hiromitsu Nakauchi

1 reference

16 May 2018

Masafumi Onodera

5

object named as

Masafumi Onodera

1 reference

16 May 2018

author name string

Tsukasa Nabekura

1

1 reference

16 May 2018

Toshiro Nagasawa

3

1 reference

16 May 2018

publication date

28 November 2005

1 reference

16 May 2018

published in

Molecular Therapy

1 reference

16 May 2018

volume

13

1 reference

16 May 2018

issue

2

1 reference

16 May 2018

page(s)

301-309

1 reference

16 May 2018

The dendritic cell system and its role in immunogenicity

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Natural adjuvants: endogenous activators of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Immunotherapy of cancer with dendritic-cell-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Dendritic cells in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Dendritic cells: immunobiology and cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Viral vectors for dendritic cell-based immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Cancer immunotherapy: synthetic and natural peptides in the balance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Cancer immunotherapy: moving beyond current vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Clinical applications of dendritic cell vaccination in the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

The use of dendritic cells in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Down-regulation of retroviral transgene expression during differentiation of progenitor-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Reciprocal roles for CCAAT/enhancer binding protein (C/EBP) and PU.1 transcription factors in Langerhans cell commitment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Adenovirus as a gene therapy vector for hematopoietic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Development of gene therapy for blood disorders by gene transfer into haematopoietic stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

CD4 T cells and their role in antitumor immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Mice lacking MHC class II molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Studies in antibody response of mice to tumour inoculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Introduction of soluble protein into the class I pathway of antigen processing and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2005.09.021

1 reference

16 May 2018

PubMed ID

16311073

1 reference

16 May 2018